4SCAR-T / SZGIMI - LARVOL DELTA

CAR-T Immunotherapy Targeting CD19- ALL (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2029 ➔ Jun 2029

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20 • CD22 • CD38 • CRLF2 • IL3RA • MME

4SCAR-T Therapy Post CD19-targeted Immunotherapy (clinicaltrials.gov) - P1/2 | N=100 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2030 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2029 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123 • CD20 • CD22 • CD38 • IL3RA • MME

Intervention of Bladder Cancer by CAR-T (clinicaltrials.gov) - P1/2 | N=20 | Terminated | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2029 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2028 ➔ Jul 2026

Trial completion date • Trial primary completion date • Trial termination • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Multi-4SCAR-T Therapy Targeting Breast Cancer (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2030 | Trial primary completion date: May 2023 ➔ Dec 2029

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • HER-2

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2030 | Trial primary completion date: Nov 2020 ➔ Dec 2029

Trial completion date • Trial primary completion date • Neuroblastoma • Oncology • Solid Tumor • CD276

4SCAR-T Therapy Post CD19-targeted Immunotherapy (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2030 | Trial primary completion date: May 2023 ➔ Dec 2029

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123 • CD20 • CD22 • CD38 • IL3RA • MME

CAR-T Immunotherapy Targeting CD19- ALL (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2029 | Trial primary completion date: Jul 2021 ➔ Jul 2028

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD20 • CD22 • CD38 • CRLF2 • IL3RA • MME

Intervention of Bladder Cancer by CAR-T (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Dec 2020 ➔ Dec 2029 | Trial primary completion date: Dec 2019 ➔ Dec 2028

Enrollment open • Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. (PubMed, Mol Cancer) - P1 | "Both single and combined infusions of GD2-specific 4SCAR-T cells in targeting GBM were safe and well tolerated, with no severe adverse events. In addition, GD2-specific 4SCAR-T cells partially mediate antigen loss and activate immune responses in the tumor microenvironment. Validation of our findings in a larger prospective trial is warranted."

CAR T-Cell Therapy • Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

CAR-T Cells Targeting Autoimmune Diseases (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute

CAR T-Cell Therapy • New P1/2 trial • Immunology